Carnitine derivatives: Clinical usefulness

Current Opinion in Gastroenterology

Volumn 28, Issue 2, 2012, Pages 166-176

  Malaguarnera, Mariano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

acetyl L carnitine; isovaleryl L carnitine; L carnitine; propionyl L carnitine; therapy

Indexed keywords

ACETOACETYL LEVO CARNITINE; AMISULPRIDE; BUTYRYL LEVO CARNITINE; CARNITINE DERIVATIVE; DECANOYL LEVO CARNITINE; DILTIAZEM; HEXANOYL LEVO CARNITINE; HYDROXYBUTYRYL LEVO CARNITINE; ISOVALERYL LEVO CARNITINE; LEVACECARNINE; ORTANOYL LEVO CARNITINE; PALMITOYL LEVO CARNITINE; PLACEBO; PROPIONYL COENZYME A; PROPIONYLCARNITINE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; STEAROYL LEVO CARNITINE; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BRAIN ISCHEMIA; BRAIN TISSUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC FATIGUE SYNDROME; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEPRESSION; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DYSTHYMIA; FIBROMYALGIA; FRAGILE X SYNDROME; HEART FAILURE; HEART HYPERTROPHY; HEPATIC COMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INOTROPISM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER CIRRHOSIS; MALE INFERTILITY; MILD COGNITIVE IMPAIRMENT; MOLECULAR MECHANICS; MUSCLE CELL; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NEUROPATHY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PEYRONIE DISEASE; PHYSICAL ACTIVITY; QUALITY OF LIFE; REPERFUSION; REVIEW; STABLE ANGINA PECTORIS; VASODILATATION;

ACETYLCARNITINE; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CARNITINE; COGNITION DISORDERS; DEPRESSION; DIABETES MELLITUS; HUMANS; LIVER CIRRHOSIS; NERVOUS SYSTEM DISEASES; NOOTROPIC AGENTS;

EID: 84858077778     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283505a3b     Document Type: Review

References (100)

1. Bieber LL. Carnitine. Annu Rev Biochem 1988; 57:261-283.
2. Brady PS, Ramsay RR, Brady LJ. Regulation of the long-chain carnitine acyltransferases. FASEB J 1993; 7:1039-1044. (Pubitemid 23243446)
3. Ramsay RR, Zammit VA. Carnitine acyltransferases and their influence on CoA pools in health and disease. Mol Aspects Med 2004; 25:475-493. (Pubitemid 39195072)
4. Zammit VA, Ramsay RR, Bonomini M, Arduini A. Carnitine, mitochondrial function and therapy. Adv Drug Deliv Rev 2009; 61:1353-1362.
5. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 2000; 1486:1-17. (Pubitemid 30336788)
6. Fukao T, Lopaschuk GD, Mitchell GA. Pathways and control of ketone body metabolism: on the fringe of lipid biochemistry. Prostaglandins Leukot Essent Fatty Acids 2004; 70:243-251. (Pubitemid 38200951)
7. Platell C, Kong SE, McCauley R, Hall JC. Branched-chain amino acids. J Gastroenterol Hepatol 2000; 15:706-717. (Pubitemid 30615052)
8. Jogl G, Hsiao YS, Tong L. Structure and function of carnitine acyltransferases. Ann N Y Acad Sci 2004; 1033:17-29. (Pubitemid 39656735)
9. Flanagan JL, Simmons PA, Vehige J, et al. Role of carnitine in disease. Nutr Metab (Lond) 2010; 7:30.
10. Abd-Allah AR, Al-Majed AA, Al-Yahya AA, et al. L-Carnitine halts apoptosis and myelosuppression induced by carboplatin in rat bone marrow cell cultures (BMC). Arch Toxicol 2005; 79:406-413. (Pubitemid 41040176)
11. Malaguarnera M, Vacante M, Giordano M, et al. L-Carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-a 2b plus ribavirin. World J Gastroenterol 2011; 17:4414-4420.
12. Mingorance C, Rodriguez-Rodriguez R, Justo ML, et al. Pharmacological effects and clinical applications of propionyl-L-carnitine. Nutr Rev 2011; 69:279-290.
13. Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998; 12:291-299. (Pubitemid 28416496)
14. Burlina AP, Sershen H, Debler EA, Lajtha A. Uptake of acetyl-L-carnitine in the brain. Neurochem Res 1989; 14:489-493. (Pubitemid 19176629)
15. Di Cesare Mannelli L, Ghelardini C, Toscano A, et al. The neuropathyprotective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010; 165:1345-1352.
16. Fiskum G. Mechanisms of neuronal death and neuroprotection. J Neurosurg Anesthesiol 2004; 16:108-110. [Review]. No abstract available.. (Pubitemid 38057413)
17. Anonymous. Acetyl-L-carnitine. Monograph. Altern Med Rev 2010; 15:76-83.
18. Carta A, Calvani M, Bravi D, Bhuachalla SN. Acetyl-L-carnitine and Alzheimer's disease: Pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci 1993; 695:324-326. (Pubitemid 23348286)
19. Zanardi R, Smeraldi E. A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia. Eur Neuropsychopharmacol 2006; 16:281-287.
20. Torrioli MG, Vernacotola S, Mariotti P, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet 1999; 87:366-368.
21. Torrioli MG, Vernacotola S, Peruzzi L, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A 2008; 146:803-812. (Pubitemid 351499783)
22. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebocontrolled study. Drugs R D 2002; 3:223-231.
23. Sima AA, Calvani M, Mehra M, Amato A, Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: An analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28:89-94. (Pubitemid 40095788)
24. Osio M, Muscia F, Zampini L, et al. Acetyl-L-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: An open label study. J Peripher Nerv Syst 2006; 11:72-76. (Pubitemid 43344978)
25. Hart AM, Wilson AD, Montovani C, et al. Acetyl-L-carnitine: A pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004; 18:1549-1560. (Pubitemid 39037479)
26. Youle M, Osio M, ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8:241-250. (Pubitemid 46691695)
27. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl- L-carnitine. Eur J Cancer 2005; 41:1746-1750. (Pubitemid 41132636)
28. Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect f acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005; 91:135.
29. Di Marzio L, Moretti S, D'Aló S, et al. Acetyl-L-carnitine administration increases insulin-like growth factor 1 levels in asymptomatic HIV-1-infected subjects: Correlation with its suppressive effect on lymphocyte apoptosis and ceramide generation. Clin Immunol 1999; 92:103-110. (Pubitemid 29315991)
30. Rosadini G, Marenco S, Nobili F, et al. Acute effects of acetyl-L-carnitine on regional cerebral blood flow in patients with brain ischaemia. Int J Clin Pharmacol Res 1990; 10:123-128. (Pubitemid 20377887)
31. Lenzi A, Sgró P, Salacone P, et al. A placebo-controlled double-blind randomized trial of the use of combined L-carnitine and L-acetyl-carnitine treatment in men with asthenozoospermia. Fertil Steril 2004; 81:1578-1584. (Pubitemid 38749002)
32. Balercia G, Regoli F, Armeni T, et al. Placebo-controlled double-blind randomized trial on the use of L-carnitine, L-acetylcarnitine, or combined L-carnitine and L-acetylcarnitine in men with idiopathic asthenozoospermia. Fertil Steril 2005; 84:662-671. (Pubitemid 41317725)
33. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. BJU Int 2001; 88:63-67.
34. Ruggenenti P, Cattaneo D, Loriga G, et al. Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: Effects of acetyl-L-carnitine therapy. Hypertension 2009; 54:567-574.
35. McMackin CJ, Widlansky ME, Hamburg NM, et al. Effect of combined treatment with alpha-lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. J Clin Hypertens (Greenwich) 2007; 9:249-255.
36. Malaguarnera M, Pistone G, Astuto M, et al. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: Randomized double-blind, placebocontrolled trial. Dig Dis Sci 2006; 51:2242-2247.
37. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci 2008; 53:3018-3025.
38. Malaguarnera M, Vacante M, Giordano M, et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: A randomized, double-blind, placebo-controlled study. Am J Clin Nutr 2011; 93:799-808.
39. Malaguarnera M, Bella R, Vacante M, et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 2011; 46:750-759.
40. Malaguarnera M, Vacante M, Motta M, et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: A randomized and controlled clinical trial. Metab Brain Dis 2011; 26:281-289.
41. Siciliano M, Annicchiarico BE, Lucchese F, Bombardieri G. Effects of a single, short intravenous dose of acetyl-L-carnitine on pattern-reversal visualevoked potentials in cirrhotic patients with hepatic encephalopathy. Clin Exp Pharmacol Physiol 2006; 33:76-80.
42. Rossini M, Di Munno O, Valentini G, et al. Double-blind, multicenter trial comparing acetyl L-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol 2007; 25:182-188. (Pubitemid 46851421)
43. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol 2003; 18:61-71. (Pubitemid 36343974)
44. Mancuso C, Bates TE, Butterfield DA, et al. Natural antioxidants in Alzheimer's disease. Expert Opin Investig Drugs 2007; 16:1921-1931. [Review].
45. Tempesta E, Troncon R, Janiri L, et al. Role of acetyl-L-carnitine in the treatment of cognitive deficit in chronic alcoholism. Int J Clin Pharmacol Res 1990; 10:101-107. (Pubitemid 20377884)
46. Pettegrew JW, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000; 5:616-632. [Review].
47. Pettegrew JW, Levine J, Gershon S, et al. 31P-MRS study of acetyl-Lcarnitine treatment in geriatric depression: Preliminary results. Bipolar Disord 2002; 4:61-66. (Pubitemid 34567277)
48. Tempesta E, Casella L, Pirrongelli C, et al. L-Acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 1987; 13:417-423. (Pubitemid 17125265)
49. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res 1990; 16:101-106. (Pubitemid 20191237)
50. Rudman D, Sewell CW, Ansley JD. Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest 1977; 60:716-723. (Pubitemid 8180876)
51. Virmani A, Binienda Z. Role of carnitine esters in brain neuropathology. Mol Aspects Med 2004; 25:533-549. (Pubitemid 39195075)
52. Vivoli E, Di Cesare Mannelli L, Salvicchi A, et al. Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy. Neuroscience 2010; 167:1168-1174.
53. Binienda ZK, Beaudoin MA, Gough B, et al. Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl- L-carnitine and resveratrol. Neurosci Lett 2010; 480:117-121.
54. Abdul Muneer PM, Alikunju S, Szlachetka AM, Haorah J. Methamphetamine inhibits the glucose uptake by human neurons and astrocytes: stabilization by acetyl-L-carnitine. PLoS One 2011; 6:e19258.
55. Herzmann C, Johnson MA, Youle M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005; 6:344-350. (Pubitemid 43336969)
56. Ido Y, McHowat J, Chang KC, et al. Neural dysfunction and metabolic imbalances in diabetic rats. Prevention by acetyl-L-carnitine. Diabetes 1994; 43:1469-1477.
57. Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIVassociated sensory neuropathy: A systematic review and meta-analysis of randomised controlled trials. PLoS One 2010; 5:e14433.
58. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: Prevention and treatment. Clin Pharmacol Ther 2011; 90:377-387.
59. Sima AA. Acetyl-L-carnitine in diabetic polyneuropathy: Experimental and clinical data. CNS Drugs 2007; 21 (Suppl. 1):13-23.
60. Giancaterini A, De Gaetano A, Mingrone G, et al. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 2000; 49:704-708. (Pubitemid 30354575)
61. Bloomer RJ, Tschume LC, Smith WA. Glycine propionyl-L-carnitine modulates lipid peroxidation and nitric oxide in human subjects. Int J Vitam Nutr Res 2009; 79:131-141.
62. Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr 2008; 46:181-190. (Pubitemid 351215559)
63. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: Results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004; 218:103-108. (Pubitemid 38169402)
64. Kotil K, Kirali M, Eras M, et al. Neuroprotective effects of acetyl-L-carnitine in experimental chronic compression neuropathy. A prospective, randomized and placebo-control trials. Turk Neurosurg 2007; 17:67-77.
65. Paulson DJ, Traxler J, Schmidt M, et al. Protection of the ischaemic myocardium by L-propionylcarnitine: Effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc Res 1986; 20:536-541. (Pubitemid 16058117)
66. Huülsmann WC. Biochemical profile of propionyl-L-carnitine. Cardiovasc Drugs Ther 1991; 5 (Suppl. 1):7-9.
67. Siliprandi N, Di Lisa F, Menabó R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991; 5 (Suppl. 1):11-15.
68. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: An acute, intravenous, double-blind, cross-over study. Eur Heart J 1992; 13:251-255.
69. Brevetti G, Perna S, Sabbá C, et al. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol 1995; 26:1411-1416.
70. Bolognesi M, Amodio P, Merkel C, et al. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol 1995; 15:417-423.
71. Cittanti C, Colamussi P, Giganti M, et al. Technetium-99m sestamibi leg scintigraphy for noninvasive assessment of propionyl-L-carnitine induced changes in skeletal muscle metabolism. Eur J Nucl Med 1997; 24:762-766. (Pubitemid 27356855)
72. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl- L-carnitine in intermittent claudication. J Am Coll Cardiol 1999; 34:1618-1624. (Pubitemid 29528679)
73. Dal Lago A, De Martini D, Flore R, et al. Effects of propionyl-L- carnitine on peripheral arterial obliterative disease of the lower limbs: A double-blind clinical trial. Drugs Exp Clin Res 1999; 25:29-36. (Pubitemid 29199590)
74. Hiatt WR. New treatment options in intermittent claudication. J Am Coll Cardiol 1995; 26:1411-1416.
75. Ragozzino G, Mattera E, Madrid E, et al. Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: Results of a pilot trial. Drugs R D 2004; 5:185-190. (Pubitemid 39089504)
76. Signorelli SS, Fatuzzo P, Rapisarda F, et al. Propionyl-L-carnitine therapy: Effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease. Kidney Blood Press Res 2006; 29:100-107. (Pubitemid 44215215)
77. Signorelli SS, Fatuzzo P, Rapisarda F, et al. A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral rterial disease requiring haemodialysis. Drugs Aging 2006; 23:263-270.
78. Andreozzi GM, Leone A, Laudani R, et al. Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication. Angiology 2008; 59:84-89. (Pubitemid 351253090)
79. Allegra C, Antignani PL, Schachter I, et al. Propionyl-L-carnitine in Leriche- Fontaine stage II peripheral arterial obstructive disease. Ann Vasc Surg 2008; 22:552-558.
80. Sethi R, Wang X, Ferrari R, Dhalla NS. Improvement of cardiac function and beta-adrenergic signal transduction by propionyl L-carnitine in congestive heart failure due to myocardial infarction. Coron Artery Dis 2004; 15:65-71. (Pubitemid 39118002)
81. Irat AM, Aktan F, Ozansoy G. Effects of L-carnitine treatment on oxidant/ antioxidant state and vascular reactivity of streptozotocin-diabetic rat aorta. J Pharm Pharmacol 2003; 55:1389-1395. (Pubitemid 37321382)
82. Tassani V, Cattapan F, Magnanimi L, Peschechera A. Anaplerotic effect of propionyl carnitine in rat heart mitochondria. Biochem Biophys Res Commun 1994; 199:949-953. (Pubitemid 24181754)
83. Bartels GL, Remme WJ, Pillay M, et al. Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans. J Cardiovasc Pharmacol 1992; 20:157-164.
84. Lagioia R, Scrutinio D, Mangini SG, et al. Propionyl-L-carnitine: A new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 1992; 34:167-172.
85. Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994; 74:125-130. (Pubitemid 24219298)
86. Bartels GL, Remme WJ, Holwerda KJ, Kruijssen DA. Antiischaemic efficacy of L-propionylcarnitine - a promising novel metabolic approach to ischaemia? Eur Heart J 1996; 17:414-420. (Pubitemid 26131424)
87. Lango R, Smolenski RT, Narkiewicz M, et al. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res 2001; 51:21-29. (Pubitemid 32523051)
88. Cave MC, Hurt RT, Frazier TH, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 2008; 23:16-34. (Pubitemid 351438965)
89. Opasich C, Cobelli F, Tavazzi L. Clinical and instrumental indicators of chronic heart failure: Do we know how to use them? G Ital Cardiol (Rome) 1997; 27:173-180.
90. Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994; 15:1267-1273. (Pubitemid 124005617)
91. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992; 42:1101-1104.
92. Gentile V, Vicini P, Prigiotti G, et al. Preliminary observations on the use of propionyl-L-carnitine in combination with sildenafil in patients with erectile dysfunction and diabetes. Curr Med Res Opin 2004; 20:1377-1384. (Pubitemid 39361341)
93. Cavallini G, Caracciolo S, Vitali G, et al. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 2004; 63:641-646. (Pubitemid 38479399)
94. Gentile V, Antonini G, Antonella Bertozzi M, et al. Effect of propionyl- L-carnitine, L-arginine and nicotinic acid on the efficacy of vardenafil in the treatment of erectile dysfunction in diabetes. Curr Med Res Opin 2009; 25:2223-2228.
95. Gasbarrini G, Mingrone G, Giancaterini A, et al. Effects of propionyl- L-carnitine topical irrigation in distal ulcerative colitis: A preliminary report. Hepatogastroenterology 2003; 50:1385-1389. (Pubitemid 37186489)
96. Mikhailova TL, Sishkova E, Poniewierka E, et al. Randomised clinical trial: The efficacy and safety of propionyl-L-carnitine therapy in patients with ulcerative colitis receiving stable oral treatment. Aliment Pharmacol Ther 2011; 34:1088-1097.
97. Colucci S, Mori G, Vaira S, et al. L-Carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int 2005; 76:458-465. (Pubitemid 41185873)
98. Patano N, Mancini L, Settanni MP, et al. L-Carnitine fumarate and isovaleryl- L-carnitine fumarate accelerate the recovery of bone volume/total volume ratio after experimentally induced osteoporosis in pregnant mice. Calcif Tissue Int 2008; 82:221-228.
99. Benvenga S, Amato A, Calvani M, Trimarchi F. Effects of carnitine on thyroid hormone action. Ann N Y Acad Sci 2004; 1033:158-167. (Pubitemid 39656748)
100. Mingorance C, Rodríguez-Rodríguez R, Justo ML, et al. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. Vasc Health Risk Manag 2011; 7:169-176.